SAM
SLNO

Sectoral Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Sectoral Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,439
Closed -$47K – 130
2018
Q3 		$47K Buy
+1,439
New +$52.3K 0.01% 165

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sectoral Asset Management's SLNO Position: Q4 2018 in Review

Sectoral Asset Management sold out of Soleno Therapeutics (SLNO) in Q4 2018, closing a stake of 1,439 shares — an estimated $47K sold.

Sectoral Asset Management first reported a position in SLNO in Q3 2018 and held it in 1 quarter. The position peaked at $47K in Q3 2018. 19 funds tracked by Wall St. Rank hold SLNO as of Q4 2018.

  • Sectoral Asset Management reported no remaining Soleno Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sectoral Asset Management sold 1,439 Soleno Therapeutics shares in Q4 2018, an estimated $47K.
  • Sectoral Asset Management first reported a position in Soleno Therapeutics in Q3 2018 and held it in 1 quarter.
  • Sectoral Asset Management's Soleno Therapeutics position peaked at $47K in Q3 2018.
  • 19 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2018.

Based on Sectoral Asset Management's 13F filing for Q4 2018, filed 12 Feb 2019.